期刊
TRANSFUSION CLINIQUE ET BIOLOGIQUE
卷 10, 期 1, 页码 1-5出版社
EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/S1246-7820(02)00276-8
关键词
transfusion; transfusion risks; HCV; HIV; screening
The viral safety of the blood supply provided by serological tests alone decreased the residual risk of viral transmission to less than 1:250,000 for hepatitis C virus (HCV) and 1:1.3 M for HIV in the EU and the USA in 2000. This was further improved to 1:2-4 M by the introduction of nucleic acid testing (NAT) for HCV and HIV RNA that considerably reduced the risk of window period transmission. However, over the past 20 years, the successive introduction of up to 10 direct or surrogate viral markers enormously complicated the screening process and testing errors have become the main residual risk of viral transmission by transfusion. At over $ 2 M per QALY, the very low cost-effectiveness of NAT and some other tests overburdens limited funds that might be better used for other health care priorities. At the same time, haemovigilance programmes have shown that blood transfused to the wrong patient and a range of immunological consequences of transfusion caused two deaths per million transfusions and little is done to prevent them. There are means of limiting these serious hazards of transfusion that should become the priority in blood safety. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据